David Westenberg
Stock Analyst at Piper Sandler
(3.98)
# 585
Out of 4,920 analysts
165
Total ratings
47.37%
Success rate
12.06%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NEO NeoGenomics | Maintains: Overweight | $12 → $11 | $5.80 | +89.66% | 10 | Aug 4, 2025 | |
| WGS GeneDx Holdings | Maintains: Overweight | $110 → $120 | $107.38 | +11.75% | 2 | Aug 4, 2025 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $23 → $21 | $20.54 | +2.24% | 9 | Aug 4, 2025 | |
| TEM Tempus AI | Maintains: Neutral | $55 → $70 | $57.87 | +20.96% | 4 | May 15, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $2 → $1.25 | $1.40 | -10.39% | 8 | May 15, 2025 | |
| NTRA Natera | Maintains: Overweight | $205 → $210 | $138.63 | +51.48% | 15 | May 15, 2025 | |
| ILMN Illumina | Maintains: Overweight | $190 → $185 | $98.71 | +87.42% | 16 | May 15, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $205 → $210 | $147.00 | +42.86% | 14 | May 12, 2025 | |
| LH Labcorp Holdings | Maintains: Neutral | $260 → $280 | $262.46 | +6.68% | 4 | May 6, 2025 | |
| GH Guardant Health | Maintains: Overweight | $50 → $60 | $45.68 | +31.35% | 9 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $11.17 | +16.38% | 13 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $200 | $174.13 | +14.86% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.4 → $5 | $4.72 | +6.04% | 12 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $12 | $14.11 | -14.92% | 9 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8.5 → $8 | $3.87 | +106.72% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $48.00 | +45.83% | 10 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $435 → $510 | $646.17 | -21.07% | 10 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $13.33 | - | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $24.12 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $47.77 | - | 1 | Nov 21, 2017 |
NeoGenomics
Aug 4, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $5.80
Upside: +89.66%
GeneDx Holdings
Aug 4, 2025
Maintains: Overweight
Price Target: $110 → $120
Current: $107.38
Upside: +11.75%
Fulgent Genetics
Aug 4, 2025
Maintains: Neutral
Price Target: $23 → $21
Current: $20.54
Upside: +2.24%
Tempus AI
May 15, 2025
Maintains: Neutral
Price Target: $55 → $70
Current: $57.87
Upside: +20.96%
Pacific Biosciences of California
May 15, 2025
Maintains: Neutral
Price Target: $2 → $1.25
Current: $1.40
Upside: -10.39%
Natera
May 15, 2025
Maintains: Overweight
Price Target: $205 → $210
Current: $138.63
Upside: +51.48%
Illumina
May 15, 2025
Maintains: Overweight
Price Target: $190 → $185
Current: $98.71
Upside: +87.42%
Zoetis
May 12, 2025
Maintains: Overweight
Price Target: $205 → $210
Current: $147.00
Upside: +42.86%
Labcorp Holdings
May 6, 2025
Maintains: Neutral
Price Target: $260 → $280
Current: $262.46
Upside: +6.68%
Guardant Health
May 6, 2025
Maintains: Overweight
Price Target: $50 → $60
Current: $45.68
Upside: +31.35%
May 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $11.17
Upside: +16.38%
Apr 28, 2025
Maintains: Neutral
Price Target: $180 → $200
Current: $174.13
Upside: +14.86%
Apr 22, 2025
Maintains: Neutral
Price Target: $6.4 → $5
Current: $4.72
Upside: +6.04%
Mar 6, 2025
Maintains: Neutral
Price Target: $16 → $12
Current: $14.11
Upside: -14.92%
Mar 4, 2025
Maintains: Overweight
Price Target: $8.5 → $8
Current: $3.87
Upside: +106.72%
Feb 26, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $48.00
Upside: +45.83%
Feb 10, 2025
Maintains: Neutral
Price Target: $435 → $510
Current: $646.17
Upside: -21.07%
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $13.33
Upside: -
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $24.12
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $47.77
Upside: -